Diabetic Peripheral Neuropathy Pipeline Review, 2019

Diabetic peripheral neuropathy is referred as the damage of nerves, which is caused due to excessive blood sugar and diabetes. There are certain types of diabetic neuropathy such as peripheral neuropathy, proximal neuropathy, autonomic neuropathy, and focal neuropathy. Loss of sensations, acute pains or cramps, muscle weakness, loss of reflexes, and loss of balance are some of the commonly observed symptoms of diabetic peripheral neuropathy amongst others. According to the American Diabetes Association, an estimated 50.0% of diabetes patients suffer from neuropathy each year in the U.S.

At the initial phase of diabetic peripheral neuropathy, the pain is not severe, hence over the counter drugs are recommended for the treatment of initial phase of diabetic peripheral neuropathy. Currently, acetaminophen, non-steroidal anti-inflammatory drugs, and anti-depressants are widely prescribed by the physicians for the treatment of diabetic peripheral neuropathy.

Pharmaceutical companies and other drug manufacturers are prominently focusing on studying and developing new treatment options for diabetic peripheral neuropathy. For instance; ABX-1431, which is being studied by Abide Therapeutics, is currently in phase-1 clinical trials to check its efficacy and tolerability for the treatment of diabetic peripheral neuropathy.

At present, around 75% of the pipeline candidates for diabetic peripheral neuropathy are in the phase-2 and phase-3 stage. Majority of the studies have been sponsored by pharmaceutical companies and other drug manufacturers.

Report Description

The report on ‘Diabetic Peripheral Neuropathy – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Diabetic Peripheral Neuropathy. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Diabetic Peripheral Neuropathy


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Diabetic Peripheral Neuropathy


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary